Drugs / JNJ-75229414
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05022849 | Sep 2021 → Mar 2026 | prostate neoplasm | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-75229414 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05022849 ↗ |
| Modality | Cell therapy | “a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against KLK2” NCT05022849 ↗ |
| Route | Intravenous | “JNJ-75229414 infusion will be administered intravenously.” NCT05022849 ↗ |
| Target | KLK2 | “a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against KLK2” NCT05022849 ↗ |